5 Exhibitors to Visit at CPHI Worldwide Milan 2026

Amcor plc, headquartered in Zurich, Switzerland, is a packaging manufacturer with origins dating to 1860 and a current workforce of approximately 75,000 people across roughly 400 facilities in more than 40 countries. Its healthcare portfolio spans primary pharmaceutical packaging in both rigid and flexible formats, covering solid-dose blister systems, pharmaceutical bottles and closures, high-barrier medical device laminates, and connected inhalation devices.

Following its combination with Berry Global, Amcor reports approximately $23 billion in annualized sales, giving it supply capacity and regulatory support infrastructure that smaller packaging converters cannot match at equivalent geographic spread. Its AmSky blister system, a vinyl- and aluminum-free polyethylene-based thermoform format, and its nitrosamine-content-free blister solutions address two compliance pressures that are actively reshaping pharmaceutical primary packaging procurement.

Agilent Technologies India Private Limited is the Indian subsidiary of Agilent Technologies, incorporated in 1999 and headquartered in Jasola, South Delhi. The India entity employs between 1,001 and 2,000 people, supported by a global workforce of approximately 18,100. Its product scope covers gas chromatography, liquid chromatography, LC/MS, ICP-MS elemental analysis, cell analysis and lab informatics, serving pharmaceutical QC, biopharma R&D and applied-chemical testing markets.

Two infrastructure investments signal Agilent India's current direction. The India Solution Center, opened in May 2025 at its LEED Platinum Manesar office, offers end-to-end application support for GLP-1 analysis, PFAS detection and pharmaceutical quality control. The Biopharma Experience Center, launched in Hyderabad in July 2025, covers the full drug development journey across chromatography, mass spectrometry, cell analysis and lab informatics, with a focus on biologics, biosimilars, ADCs and mRNA modalities. Local application and service support spans Bangalore, Mumbai, New Delhi, Hyderabad, Ahmedabad, Chennai, Chandigarh and Kolkata.

Malvern Panalytical, headquartered in Malvern, United Kingdom with major operations in Almelo, Netherlands, was formed in January 2017 through the merger of Malvern Instruments and PANalytical. The company employs approximately 2,500 people globally and operates within Spectris plc's Materials Analysis segment. Its instrument portfolio spans laser-diffraction particle sizing (Mastersizer 3000+), dynamic light scattering and zeta potential (Zetasizer Advance Ultra), X-ray diffraction (Aeris XRD, Empyrean), X-ray fluorescence (Epsilon range), and automated morphological imaging with Raman identification (Morphologi 4-ID), covering pharmaceutical R&D through batch-release QC.

Malvern Panalytical is the only analytical X-ray equipment supplier that develops and manufactures its own X-ray tubes in-house, a capability that underpins the performance of its XRD and XRF platforms across more than 2,500 documented user sites. Its OmniTrust software delivers 21 CFR Part 11 compliance for regulated pharmaceutical environments, and a 2024 collaboration with Xenocs extended its application reach into nucleic acid drug products including mRNA therapeutics and lipid nanoparticle formulations. The portfolio holds more than 250 patents across its combined brand heritage.

Azelis (India) Private Limited, headquartered in Navi Mumbai, is the Indian operating entity of Azelis Group, a specialty chemicals and food ingredients distributor present in 64 countries with over 4,100 employees and €4.1 billion in turnover as of 2025. The India business, established in 2012 and built through a series of acquisitions including Zhaveri Pharma, MK Ingredients, Spectrum Chemicals, Chemo India, and S. Amit Group, carries 75-plus years of combined local market presence. Its portfolio spans pharmaceutical excipients, APIs, food and nutrition, personal care, CASE, lubricants, agro, and home care across nine active market segments, serving more than 2,100 customers in India.

For pharma buyers specifically, Azelis India operates local application laboratories that provide formulation development support and technical seminars, reducing the gap between ingredient sourcing and dosage form development. In June 2026 the company announced a distribution partnership with Lactalis for the Lactalpha pharmaceutical lactose range, a milled and sieved low-nitrite lactose for tablets, sachets, and capsules that complies with Ph. Eur., USP-NF, and JP monographs. This addition extends an excipient portfolio that already includes functional coating systems such as EUDRAGIT IR Readymix White and EUDRAGIT FL 30 D-55 for controlled-release oral solid dosage programs.

GE HealthCare Technologies Inc., headquartered in Chicago, Illinois, operates as an independent publicly traded company following its spin-off from General Electric on January 3, 2023. Its Pharmaceutical Diagnostics division supplies contrast media and molecular imaging agents used across CT, radiographic, MRI, and SPECT imaging modalities, with a product portfolio anchored by Omnipaque (iohexol), Visipaque (iodixanol), Omniscan (gadodiamide), and DaTscan (ioflupane I-123).

The PDx business runs seven cGMP-accredited, vertically integrated manufacturing plants that cover active pharmaceutical ingredient production through to finished product. Output exceeds 80 million vials of contrast media and approximately 100 million imaging agent doses per year, a scale that positions the division as a significant supplier to hospital radiology departments, nuclear medicine facilities, and CDMO fill-finish partners requiring reliable, high-volume diagnostic agent supply.